An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
|
journal
|
October 2020 |
Antibody-antigen interactions
|
journal
|
February 1993 |
Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil
|
journal
|
April 2021 |
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
|
journal
|
October 2020 |
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
|
journal
|
August 2021 |
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
|
journal
|
November 2020 |
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
|
journal
|
January 2021 |
Selection of an ASIC1a-blocking combinatorial antibody that protects cells from ischemic death
|
journal
|
July 2018 |
A cell–cell interaction format for selection of high-affinity antibodies to membrane proteins
|
journal
|
July 2019 |
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
|
journal
|
July 2020 |
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
|
journal
|
August 2021 |
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
|
journal
|
April 2020 |
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
|
journal
|
June 2021 |
Selection of Human Metalloantibodies from a Combinatorial Phage Single-Chain Antibody Library
|
journal
|
June 1999 |
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
|
journal
|
July 2020 |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
|
journal
|
October 2020 |
Broad neutralization of SARS-related viruses by human monoclonal antibodies
|
journal
|
June 2020 |
The COVID-19 pandemic and human fertility
|
journal
|
July 2020 |
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
|
journal
|
November 2020 |
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
|
journal
|
July 2020 |
A human monoclonal antibody blocking SARS-CoV-2 infection
|
journal
|
May 2020 |
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
|
journal
|
March 2021 |
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
|
journal
|
July 2011 |
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
|
journal
|
December 2020 |
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
|
journal
|
September 2020 |
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
|
journal
|
August 2020 |
Inference of Macromolecular Assemblies from Crystalline State
|
journal
|
September 2007 |
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
|
journal
|
November 2020 |
Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library
|
journal
|
February 2021 |
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
|
journal
|
August 2020 |
Evolution of antibody immunity to SARS-CoV-2
|
journal
|
January 2021 |
Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
|
journal
|
January 2021 |
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
|
journal
|
May 2021 |
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
|
journal
|
March 2021 |
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
|
journal
|
September 2020 |
Structural basis of a shared antibody response to SARS-CoV-2
|
journal
|
July 2020 |
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
|
journal
|
April 2020 |
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
|
journal
|
February 2021 |
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
|
journal
|
June 2020 |
Antibody selection using clonal cocultivation of Escherichia coli and eukaryotic cells in miniecosystems
|
journal
|
June 2018 |
Potently neutralizing and protective human antibodies against SARS-CoV-2
|
journal
|
July 2020 |
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
|
journal
|
March 2021 |
Antibody Structure
|
journal
|
March 2014 |
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
|
journal
|
February 2021 |
Detection of a SARS-CoV-2 variant of concern in South Africa
|
journal
|
March 2021 |
Coot model-building tools for molecular graphics
|
journal
|
November 2004 |
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
|
journal
|
August 2018 |
Rare antibodies from combinatorial libraries suggests an S.O.S. component of the human immunological repertoire
|
journal
|
January 2011 |
Neutralizing antibodies targeting SARS-CoV-2 spike protein
|
journal
|
January 2021 |
Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells
|
journal
|
April 2013 |
Combinatorial antibody libraries: new advances, new immunological insights
|
journal
|
July 2016 |
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
|
journal
|
March 2020 |
Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo
|
journal
|
October 2020 |
PHENIX: a comprehensive Python-based system for macromolecular structure solution
|
journal
|
January 2010 |
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|
journal
|
January 2021 |
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
|
journal
|
June 2020 |
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
|
journal
|
June 2020 |
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
|
journal
|
July 2021 |
Immunology of COVID-19: Current State of the Science
|
journal
|
June 2020 |
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
|
journal
|
June 2020 |
Identification of Human Single-Domain Antibodies against SARS-CoV-2
|
journal
|
June 2020 |
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
|
journal
|
May 2020 |
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
|
journal
|
May 2021 |
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis
|
journal
|
November 2004 |
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|
journal
|
March 2020 |
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
|
journal
|
August 2020 |
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
|
journal
|
July 2020 |
[20] Processing of X-ray diffraction data collected in oscillation mode
|
book
|
January 1997 |
IgBLAST: an immunoglobulin variable domain sequence analysis tool
|
journal
|
May 2013 |
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
|
journal
|
July 2020 |
Phaser crystallographic software
|
journal
|
July 2007 |
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
|
journal
|
June 2020 |